The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. 1 Noyce RS, et al.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

Broad Institute

MAY 21, 2025

He showed that these synthetic CAR T cells could launch an immune response when they encountered the corresponding tumor protein, called CD19. Our initial work with engineered T cells in HIV patients revealed that these cells could persist in the body far longer than anticipated, said June, who is the Richard W.

Therapies 119

Therapies FDA Approval Engineering Immune Response 119

BioPharma Drive: Drug Pricing

JUNE 27, 2025

Published June 27, 2025 Ned Pagliarulo Lead Editor post share post print email license Bristol Myers Squibb sells two CAR-T cell therapies for cancer. These medicines are made from a patient’s own immune cells, extracted from the body and engineered in a lab to hunt down specific proteins found on the surface of malignant clones.

Therapies 182

Therapies FDA Treatment Licensing 182

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Licensing 52

Licensing Licensing Therapies Engineering 52

Codon

FEBRUARY 13, 2024

Phage-based products have been licensed for use as antibacterial agents in the sanitation , food production , and animal health industries. Crucially, it could also make them easier to license as therapeutic agents. The resulting data are fed into an analytical engine that runs millions of simulations. aeruginosa, S. pneumoniae.

Therapies 136

Therapies Virus DNA Clinical Trials 136

Drug Target Review

OCTOBER 10, 2024

In the context of preclinical research, using healthy cells to study disease-specific mechanisms, cell-cell interactions, and immune responses can result in faulty data, missed therapeutic targets, and unanticipated immune responses.

Therapies 52

Therapies Immune Response Clinical Trials Disease 52

The Pharma Data

AUGUST 3, 2021

The company announced donanemab received Breakthrough Therapy designation for treatment of Alzheimer’s disease and its intention to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. Loxo Oncology at Lilly and Kumquat Biosciences Inc.

Production 52

Production Marketing Research Government 52

Codon

JULY 27, 2023

But for a recent paper out of Nanjing, China, researchers engineered another enzyme and showed that, when mixed with FAST-PETase, the two worked together to break down plastic twice as fast as the Texas enzyme alone. a lower risk of immune responses. They don’t always break down PET into a form that is easily recycled.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

But for a recent paper out of Nanjing, China, researchers engineered another enzyme and showed that, when mixed with FAST-PETase, the two worked together to break down plastic twice as fast as the Texas enzyme alone. a lower risk of immune responses. They don’t always break down PET into a form that is easily recycled.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

SEPTEMBER 29, 2024

At best, the corporations with the best models released weak versions to the public under non-commercial licenses. The new viruses could shuffle surface antigens after encountering an immune response, rapidly adopt new conformations to fit through tight cellular junctions, and self-replicate at safe background levels for years on end.

Engineering 144

Engineering Virus DNA Therapies 144

The Pharma Data

DECEMBER 20, 2020

platform and its patented large-capacity VV cop TK-RR- oncolytic virus, which has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR ® /F.I.R.S.T BT-001 is a best-in-class oncolytic Vaccinia virus. It has been generated using Transgene’s Invir.IO

Virus 40

Virus Trials Clinical Trials Clinical Development 40

Codon

JULY 14, 2024

This is particularly beneficial for those who need chronic transfusions and are therefore at risk of developing an immune response to transfusion products from other people, or for those with religious beliefs, like Jehovah’s Witnesses, whose faith prohibits blood transfusions from another person.

Production 143

Production Clinical Trials Trials Therapies 143

The Pharma Data

SEPTEMBER 15, 2020

With the depth and breadth of our current portfolio, the tremendous potential of our pipeline and scientific engine, and the power of our culture of innovation, we are poised to continue delivering meaningful value to patients by addressing some of the world’s most difficult health challenges.”.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

Codon

APRIL 16, 2023

Codon Digest is my weekly roundup of research, news, and industry highlights about engineered biology. Skin microbes can trigger strong immune responses. In other words: Brush some engineered bacteria on the skin, and they activate the immune system to go fight a tumor. Metabolic Engineering. Wichmann J.

Engineering 52

Engineering DNA RNA Science 52

The Pharma Data

SEPTEMBER 8, 2020

Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52